{"created":"2023-06-19T07:25:15.808579+00:00","id":12926,"links":{},"metadata":{"_buckets":{"deposit":"b148d1c2-f7cd-44ab-bdd1-1453019a18ba"},"_deposit":{"created_by":4,"id":"12926","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"12926"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00012926","sets":["147:216"]},"author_link":["17966","17965","17964"],"item_1_biblio_info_14":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-06-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"7","bibliographicPageStart":"1","bibliographicVolumeNumber":"59","bibliographic_titles":[{"bibliographic_title":"岐阜薬科大学紀要　"},{"bibliographic_title":"The annual proceedings of Gifu Pharmaceutical University","bibliographic_titleLang":"en"}]}]},"item_1_creator_6":{"attribute_name":"著者名(日)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"永井, 博弌"}],"nameIdentifiers":[{"nameIdentifier":"17964","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_7":{"attribute_name":"著者名よみ","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ナガイ, ヒロイチ"}],"nameIdentifiers":[{"nameIdentifier":"17965","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_8":{"attribute_name":"著者名(英)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NAGAI, Hiroichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"17966","nameIdentifierScheme":"WEKO"}]}]},"item_1_description_1":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P(論文)","subitem_description_type":"Other"}]},"item_1_description_11":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"多くの脂質メディエーターはアレルギーなど炎症性疾患の発症に関与することがよく知られている。しかし、\n近年、ある種の脂質メディエーターには炎症を終焉させ、炎症の終息に大きな役割を有することが明らかにされた。この\nような抗炎症性脂質メディエーターの発見は炎症の病態や治療薬の開発に新しい局面を開くものとして注目されている。\nすなわち、我々の研究室ではこれまでに、プロスタグランジン(PG)受容体遺伝子欠損マウスや５－リポキシゲナーゼ(LO)\n欠損マウスを用いた研究から、PGD2 およびロイコトリエン類にアレルギー発症因子としての意義を見出し、同時にPGE2\nおよび PGI2 にはアレルギー発症制御因子としての役割があることを明らかにしてきた。加えて、最近の研究ではLO 系\n産物のリポキシンおよびオメガー３から産生されるレゾルビンに炎症終焉物質としての意義が見出され、脂質メディエー\nターはアレルギー発症の促進因子と抑制因子が同時に病態時に産生され、病勢や病気の進展に関与する可能性が示されて\nいる。さらに、脂質メディエーターにかかわる代謝酵素、受容体などの遺伝子が脂質メディエーターに関わる薬物の薬効\nに影響することが最近の研究から次第に明らかにされ、脂質メディエーターはアレルギー疾患治療薬のファーマコゲノミ\nックスの標的分子としても注目を集めている。本稿では、これまでの我々の知見と最近の報告についてまとめて述べる。","subitem_description_type":"Other"}]},"item_1_description_12":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"The purpose of this review is to summarize the role of lipid mediators in allergic inflammation and to understand the\nvalue of lipid, as a target molecule for anti-allergic drugs. PGD2 is the major PG product produced by the cyclooxygenase pathway in\nmast cells during an allergic reaction. Our findings, in addition to others, indicated that PGD2 is a potent allergic inflammatory\nmediator and must be a target molecule of anti-allergic agents. Concerning the role of PGE2 in allergic inflammation, conflicting\nresults have been reported. Many investigators have suggested an individual role for each PGE2 receptor, EP1, EP2, EP3 and EP4 in\nallergic reactions. Our results indicated the protective action of PGE2 on an allergic reaction via EP3. These findings indicated the\nvalue of EP3 agonists as an anti-allergic agent. In addition, some investigators, including us reported that PGI2 plays an important\nrole in the protection from allergic reaction. However, the efficacy of PGI2 analogue as an anti-allergic agent has not yet been fully\ninvestigated. In addition to our findings, some recent investigators have shown the protective role of lipoxin and resolvin in allergic\ninflammation. In this review, the role of PGs in allergic inflammation is summarized and the value of PGs and other lipid mediators\nas a target molecule for developing a new anti-allergic agent will be discussed.","subitem_description_type":"Other"}]},"item_1_source_id_13":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA1258935X","subitem_source_identifier_type":"NCID"}]},"item_1_text_10":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Gifu Pharmaceutical University"}]},"item_1_text_2":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_text_value":"総説"}]},"item_1_text_3":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Review"}]},"item_1_text_9":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"岐阜薬科大学"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2014-07-28"}],"displaytype":"detail","filename":"アレルギー疾患における脂質メディエーターの役割.pdf","filesize":[{"value":"571.1 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"アレルギー疾患における脂質メディエーターの役割","url":"https://gifu-pu.repo.nii.ac.jp/record/12926/files/アレルギー疾患における脂質メディエーターの役割.pdf"},"version_id":"703164e6-b566-4ecd-a28a-3f5ca55c5e20"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"脂質メディエーター","subitem_subject_scheme":"Other"},{"subitem_subject":"プロスタグランジン","subitem_subject_scheme":"Other"},{"subitem_subject":"レゾルビン","subitem_subject_scheme":"Other"},{"subitem_subject":"リポキシン","subitem_subject_scheme":"Other"},{"subitem_subject":"パーソナル医療","subitem_subject_scheme":"Other"},{"subitem_subject":"bronchial asthma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"goal of pharmacotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"treatment guideline","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"polymorphism in a gene","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"アレルギー疾患における脂質メディエーターの役割  ―アレルギー疾患治療薬の標的分子として―","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"アレルギー疾患における脂質メディエーターの役割  ―アレルギー疾患治療薬の標的分子として―"},{"subitem_title":"The role of lipid mediators in allergic reaction  — As a target molecule for drug discovery","subitem_title_language":"en"}]},"item_type_id":"1","owner":"4","path":["216"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-07-28"},"publish_date":"2014-07-28","publish_status":"0","recid":"12926","relation_version_is_last":true,"title":["アレルギー疾患における脂質メディエーターの役割  ―アレルギー疾患治療薬の標的分子として―"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-19T09:02:44.503720+00:00"}